Stéphane van Rooijen, Dynacure CEO

A year af­ter with­draw­ing IPO, Dy­nacure scraps lead drug for rare mus­cle dis­eases

The French biotech Dy­nacure is scrap­ping its lead drug af­ter run­ning in­to trou­ble dur­ing an ear­ly-stage study.

While at­tempt­ing to move from the low-dose co­hort to a high-dose in a Phase I/II study for DYN-101, the com­pa­ny ob­served el­e­vat­ed liv­er en­zyme lev­els in six pa­tients at the low­er dose, per a let­ter from CMO Chris Fre­itag to the af­fect­ed pa­tient com­mu­ni­ty. Though re­searchers tried to change the dose lev­el re­quired to move for­ward and spread out dos­ing, the com­pa­ny failed to see signs of clin­i­cal ben­e­fit and de­cid­ed to ter­mi­nate the study.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.